# Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07276789/  
OnCo record `nct07276789` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of LS301-IT 0.1 mg/kg in non-small-cell lung cancer, run by Integro Theranostics, now recruiting.

## Summary

Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07276789 by Integro Theranostics, with 35 participants planned, started 2025-12-08 and due to reach its primary completion in 2026-08. Interventions recorded: LS301-IT 0.1 mg/kg.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07276789
- Phase: 2
- Setting: A Phase 2, Open-Label, Multicenter Study to Investigate the Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Lung Cancer Resection
- Sponsor: Integro Theranostics
- Enrolled: 35

## Sources

- ClinicalTrials.gov NCT07276789: https://clinicaltrials.gov/study/NCT07276789

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct07276789.json